Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer

被引：0
|
作者：
Makoto Sudo
Tan Min Chin
Seiichi Mori
Ngan B. Doan
Jonathan W. Said
Makoto Akashi
H. Phillip Koeffler
机构：
[1] National University of Singapore,Cancer Science Institute
[2] National University Hospital,Department of Hematology and Oncology
[3] The Cancer Institute,Department of Cancer Genomics
[4] Japanese Foundation for Cancer Research,Department of Pathology and Laboratory Medicine
[5] University of California,Research Center for Radiation Emergency
[6] National Institute of Radiological Sciences,Division of Hematology and Oncology
[7] Cedars-Sinai Medical Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2013年 / 71卷
关键词：
Non-small cell lung cancer (NSCLC); Tyrosine kinase inhibitor (TKI); EGFR; 17-DMAG; Belinostat; Combination chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：1325 / 1334
页数：9
相关论文
共 50 条
  • [1] Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
    Sudo, Makoto
    Chin, Tan Min
    Mori, Seiichi
    Doan, Ngan B.
    Said, Jonathan W.
    Akashi, Makoto
    Koeffler, H. Phillip
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1325 - 1334
  • [2] Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer
    Sin, Thomas K.
    Wang, Fengfeng
    Meng, Fei
    Wong, S. C. Cesar
    Cho, William C. S.
    Siu, Parco M.
    Chan, Lawrence W. C.
    Yung, Benjamin Y. M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (02)
  • [3] Atractyloside inhibits gefitinib-resistant non-small-cell lung cancer cell proliferation
    Yao, Wanxin
    Liu, Chen
    Zhang, Ningyin
    Zhang, Yanmei
    Qian, Yong
    ONCOLOGY LETTERS, 2024, 28 (04)
  • [4] Effect of opioid receptor agonists in gefitinib-resistant non-small cell lung cancer
    Suzuki, Atsuo
    Kuzumaki, Naoko
    Hosoya, Takahiro
    Narita, Michiko
    Tsukiji, Kozue
    Suzuki, Masami
    Uezono, Yasuhito
    Morita, Hiroshi
    Suzuki, Tsutomu
    Narita, Minoru
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 : 105P - 105P
  • [5] Dominant FGF Autocrine Signaling in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells
    Heasley, Lynn E.
    Marek, Lindsay
    Fritzsche, Alexa
    Helton, Wallace R.
    Nemenoff, Raphael A.
    McDermott, Lee A.
    Helfrich, Barbara
    Bunn, Paul A.
    FASEB JOURNAL, 2008, 22
  • [6] In Vitro and in Vivo Efficacy of NBDHEX on Gefitinib-resistant Human Non-small Cell Lung Cancer
    Sha, Huanhuan
    Dong, Shuchen
    Yu, Chen
    Zou, Renrui
    Zhu, Yue
    Lu, Ya
    Zhang, Junying
    Cao, Haixia
    Chen, Dan
    Wu, Jianzhong
    Feng, Jifeng
    JOURNAL OF CANCER, 2020, 11 (24): : 7216 - 7223
  • [7] Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway
    Li, Xia
    Fan, Xing-Xing
    Jiang, Ze-Bo
    Loo, Wings T. Y.
    Yao, Xiao-Jun
    Leung, Elaine Lai-Han
    Chow, Louis W. C.
    Liu, Liang
    PHARMACOLOGICAL RESEARCH, 2017, 115 : 45 - 55
  • [8] Potential roles of tumor microenvironment in gefitinib-resistant non-small cell lung cancer: A narrative review
    Chen, Mu-Tong
    Li, Bai-Zhi
    Zhang, En-Pu
    Zheng, Qing
    MEDICINE, 2023, 102 (40) : E35086
  • [9] The Mechanisms of the Growth Inhibitory Effects of Paclitaxel on Gefitinib-resistant Non-small Cell Lung Cancer Cells
    Mohiuddin, Md
    Kasahara, Kazuo
    CANCER GENOMICS & PROTEOMICS, 2021, 18 (05) : 661 - 673
  • [10] Clinical Significance of Erlotinib Monotherapy for Gefitinib-resistant Non-small Cell Lung Cancer with EGFR Mutations
    Koyama, Nobuyuki
    Uchida, Yoshitaka
    ANTICANCER RESEARCH, 2013, 33 (11) : 5083 - 5089
12345